Exchange: NYSE·Updated 07:39 PM EST

BHVN News

News
all
press releases
Biohaven (NYSE:BHVN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
JPMorgan Chase & Co. increased their target price on Biohaven from $14.00 to $35.00 and gave the stock an "overweight" rating in a report on Thursday...
MarketBeat
Biohaven (NYSE:BHVN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
JPMorgan Chase & Co. increased their target price on Biohaven from $14.00 to $35.00 and gave the stock an "overweight" rating in a report on Thursday...
MarketBeat
More News
Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026 Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows...
PR Newswire
Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific...
PR Newswire
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial ResultsPR NewswireNEW HAVEN, Conn., Oct. 29, 2026 The US Food and Drug Administration (FDA) accepted new drug application...
PR Newswire
The average of price targets set by Wall Street analysts indicates a potential upside of 43.5% in Biohaven Ltd. (BHVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively...
PR Newswire
Today’s market spotlight spans companies navigating critical catalysts; NeOnc Technologies Holdings (NASDAQ:NTHI) is drawing attention with brain-cancer research milestones and a closely watched technical rebound setup; BIO-key International, (NASDAQ:BKYI) is expanding its government cybersecurity footprint in the Gulf; STAK (NASDAQ:STAK) is working to build on a return to profitability; Biohaven (NYSE:BHVN) faces pivotal clinical and regulatory questions across its drug pipeline; Exascale Labs Holdings (NASDAQ:XLAB) is pursuing AI infrastructure growth following a multimillion-dollar GPU server agreement; and WISeSat.Space (NASDAQ:SAIQ) is advancing satellite-based cybersecurity and post-quantum communications.
24-7 Market News
The U.S. Food and Drug Administration accepted Biohaven’s resubmitted application for its experimental neurological disease drug, Vyglxia.
Stocktwits
Gainers Biohaven (NYSE:BHVN) shares increased by 39.3% to $16.37 during Thursday's pre-market session. The company's market cap stands at $1.7 billion. Vogenx (NASDAQ:VOGX) stock rose 22.05% to $24.89. Theread more...
Benzinga
Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents.
Stocktwits

Advertisement|Remove ads.